Genotyping Of Warfarin Patients Will Be Discussed By FDA's Clinical Pharmacology Subcommittee
This article was originally published in The Pink Sheet Daily
The subcommittee will consider whether warfarin labeling should be changed to recommend lower starting doses for patients with certain genotypes at Nov. 14-15 meeting.
You may also be interested in...
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.
FDA’s Oncologic Drugs Advisory Committee will meet in Atlanta to review Bristol’s multi-targeted kinase inhibitor dasatinib for two leukemia indications.
FDA’s Psychopharmacologic Drugs Advisory Committee rules safety for modafinil product in children with attention deficit/hyperactivity disorder has not been adequately demonstrated.